Glioblastoma organoids
Glioblastoma organoids grow a patient's brain tumor in three dimensions while preserving its internal diversity, the property that makes glioblastoma so lethal and so good at defeating single-target drugs.
Glioblastoma kills because it is many tumors at once and because it invades rather than sits still. A model that homogenizes it into one cell type erases exactly the feature that matters. Patient-derived GBM organoids keep the heterogeneity, which is why they have become a serious screening tool rather than a curiosity.
Why heterogeneity is the whole problem
A single glioblastoma contains genetically and functionally distinct subpopulations, including treatment-resistant glioma stem cells, side by side. A drug can clear the sensitive cells and leave the resistant ones to regrow, which is the usual clinical story. Patient-derived GBM organoids and the biobanks built from them preserve this intra-tumoral diversity and recapitulate features of the parent tumor, so a screen can see whether a therapy hits the resistant fraction or only the easy targets.22
Invasion and the barrier problem
Glioblastoma's defining behavior is diffuse invasion into surrounding brain, which is why surgery rarely removes all of it. Three-dimensional organoid and organoid-on-chip models can reproduce invasive migration into a surrounding matrix, giving a readout for anti-invasive compounds that a flat assay cannot. For drugs meant to act in the brain, the same systems can incorporate a blood-brain-barrier layer, because a compound that cannot cross it will fail regardless of how well it kills tumor cells in a dish.
Frequently asked questions
What is a glioblastoma organoid?
A three-dimensional culture grown from a patient's glioblastoma that preserves the tumor's internal cellular diversity and invasive behavior, used to test therapies.
Why does tumor heterogeneity matter for screening?
Because glioblastoma contains resistant subpopulations alongside sensitive ones. A model that preserves them shows whether a drug clears the resistant cells or only the easy targets that would regrow.
Can GBM organoids model invasion and the blood-brain barrier?
Yes. 3D and chip-based models can reproduce invasive migration into a surrounding matrix and can incorporate a blood-brain-barrier layer to test whether a drug can reach the tumor.
References
- Jacob F, et al. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell. 2020;180(1):188-204. doi:10.1016/j.cell.2019.11.036. Accessed 2026-06-12.
- Drost J, Clevers H. Organoids in cancer research. Nature Reviews Cancer. 2018;18(7):407-418. doi:10.1038/s41568-018-0007-6. Accessed 2026-06-12.